RFK Jr. Says He's a 'BIG FAN' of Peptide Injections - Pushes for Deregulation

Health and Human Services Secretary Robert F. Kennedy Jr. is drawing attention to the peptide market as the FDA prepares to consider whether restrictions on certain peptide injections should be eased.

According to the article, the FDA is expected to hold discussions in July about whether more than a half dozen peptide injections could be added to a list of substances that may be safely compounded by pharmacies. The review comes as public interest in peptides continues to grow, especially among wellness influencers, fitness communities, longevity clinics, and consumers interested in recovery, weight management, muscle support, and anti-aging trends.

Peptides are short chains of amino acids that help regulate biological functions in the body. Some peptide-based medications, including GLP-1 drugs such as Ozempic, are already widely known for their role in appetite control and weight loss. Other peptides, such as BPC-157, are marketed for injury recovery, tendon support, gut health, and inflammation, though many have not been fully reviewed by the FDA for safety and effectiveness.

Kennedy has spoken publicly about his interest in peptides, including during an appearance on “The Joe Rogan Experience,” where he reportedly called himself a “big fan of peptides.” He also said he hopes some peptides can become more accessible through ethical suppliers.

The FDA, however, continues to urge caution. In a February advisory, the agency stated that compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug. That warning reflects the larger tension in the peptide market: public demand is rising quickly, but regulations, safety standards, and access rules are still evolving.

The article highlights a major turning point for the peptide industry. If the FDA moves toward easing restrictions, compounding pharmacies and peptide-focused businesses could see new opportunities. At the same time, regulators and medical experts continue to emphasize the need for safety, quality control, and responsible oversight.

Credit: This brief summary is based on reporting originally published by FOX News.

Editor’s Note: This article is intended solely for research, educational, and industry discussion purposes. It does not promote, recommend, or imply any personal use, medical use, health benefit, treatment outcome, or therapeutic application of peptides or related compounds.